What is known and objective: Interventions intended to slow the emergence and spread of antibacterial resistance through enhanced antimicrobial stewardship will be more effective if informed by an accurate knowledge of current patterns of antibacterial consumption. For example, knowledge of the relative magnitude of community antibacterial consumption in relation to hospital antibacterial consumption within each nation or region should help guide decisions about the relative importance of community and hospital antimicrobial stewardship programmes. It is commonly stated that community antibacterial consumption comprises approximately 80% of total national antibacterial consumption. We aimed to determine this proportion across a large range of nations.
Summary
What is known and objective: Interventions intended to slow the emergence and spread of antibacterial resistance through enhanced antimicrobial stewardship will be more effective if informed by an accurate knowledge of current patterns of antibacterial consumption. For example, knowledge of the relative magnitude of community antibacterial consumption in relation to hospital antibacterial consumption within each nation or region should help guide decisions about the relative importance of community and hospital antimicrobial stewardship programmes. It is commonly stated that community antibacterial consumption comprises approximately 80% of total national antibacterial consumption. We aimed to determine this proportion across a large range of nations.
Methods:
We measured community and hospital antibacterial consumption in New Zealand during 2015, from both reimbursement and purchase data, and compared the New Zealand data with those reported from a large range of other nations during similar time periods.
Results and discussion: Community antibacterial consumption comprised approximately 85%-95% of total antibacterial consumption in all nations for which data were available, and in New Zealand comprised a higher proportion than in any other nation.
The proportion of total antibacterial consumption comprised by community consumption was significantly higher in countries with relatively high levels of total antibacterial consumption than in countries with relatively low levels of total antibacterial consumption.
What is new and conclusion:
The high proportion of total antibacterial consumption comprised by community antibacterial consumption suggests devoting particular attention to improved community antimicrobial stewardship. These results suggest that improving antimicrobial stewardship in the community may provide greater overall benefits in combating antibacterial resistance than improving antimicrobial stewardship in hospitals.
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| WHAT IS KNOWN AND OBJECTIVE
Concern about the threats posed by rising levels of antibacterial resistance has intensified efforts to modify the factors that foster the spread of antibacterial-resistant microbes.
1,2 Antibacterial consumption places strong selective pressure on the microbes that colonize people, and in developed countries is the major determinant of the rate of increase in the prevalence of antibacterial resistance. 3 At the individual level, recent treatment with an antibacterial increases the risk that subsequent infections will be caused by an organism resistant to that antibacterial. 4 At the population level, in nations that have relatively low reported levels of antibacterial consumption (such as the Netherlands) the prevalence of antibacterial resistance tends to increase slowly, whereas in nations that have relatively high levels of antibacterial consumption (such as Greece) the prevalence of antibacterial resistance tends to increase more rapidly. In contrast, analysis of data from many European nations reported that the proportion of total consumption comprised by community consumption during 2002 ranged between 82% in Finland and 94% in Slovakia. 11 Despite these more recent findings, the assertion that community consumption comprises approximately 80% of total national consumption continues to be widely repeated. 12, 13 To estimate the current proportion of total human antibacterial consumption in New Zealand comprised by community consumption, we used administrative claims data comanaged by the New Zealand
Ministry of Health and the Pharmaceutical Management Agency (PHARMAC). We then compared the level of community antibacterial consumption in New Zealand with those in a range of other countries, using contemporary data sources.
| METHODS
PHARMAC provided data for all antibacterials dispensed in the community, including medicines dispensed in response to practitioner supply orders (PSO) and bulk supply orders (BSO), and for all antibacterials purchased by publicly funded hospitals, throughout New
Zealand, between 1 January 2015 and 31 December 2015. The data were extracted from the NZ Pharmaceuticals Collection administrative reimbursement claims database 14 , aggregating total tonnage weights for each antibacterial as reported in previous studies. 15, 16 Community data included both reimbursement data for prescribed items dispensed by all community pharmacies to individual patients plus sales data for antibacterials dispensed in bulk directly to community practitioners that could then be supplied, by these practitioners, directly to patients during consultations. Hospital antibacterial purchase data for all publicly funded hospitals were extracted from PHARMAC's hospital purchases database. For drugs containing antibacterial and non-antibacterial components (eg, enzyme inhibitors), tonnages were adjusted to account for the antibacterial components alone.
Substances included in the WHO Anatomical Therapeutic
Chemical ( Table 2 ).
| RESULTS AND DISCUSSION
The proportion of total reported antibacterial consumption comprised by community consumption internationally ranged between 85.6% and 95.1% (median 91.8%, Table 3 ). The proportion of total antibacterial consumption comprised by community consumption was significantly higher in countries with relatively high levels of total antibacterial consumption (eg, Greece, France, Belgium, Italy and New Zealand) than in countries with relatively low levels of total antibacterial consumption (eg, Sweden, Denmark, Finland, Canada; R 2 = 36.7% P < .001; Figure 1 ).
This study indicates that in a large number of developed countries community antibacterial consumption currently comprises 86%-95% of total national consumption. These results contrast with the widely repeated statement that community consumption comprises approximately 80% of total human antibacterial consumption. 12, 13 We found that 95% of the antibacterials dispensed in New Zealand were dispensed in the community and only 5% were dispensed in hospi- Differences between countries in the reported levels of community and hospital antibacterial consumption will have been, in part, due to differences between those countries in: the proportion of the population comprised by children and young people, the incidence of infectious diseases in the community, and the proportion of patients
ATC codes

DDD per 1000 inhabitants per day (%)
Community
Hospital Total with infectious diseases who received care in a hospital rather than in the community. Furthermore, there are inherent limitations in the use of administrative data to calculate the amounts of antibacterials dispensed in the community and in hospitals, with potential confounding from both the quality and the completeness of these data. The countries included in this study differed with regard to whether they used sales data, reimbursement data, or both of these types of data to calculate annual total community and total hospital consumption.
JO1A
Finally, the comparisons between countries are based on total community and hospital antibacterial consumption and therefore do not allow comparisons between countries of the relative contributions made by different antibacterial classes (or by broad-spectrum and narrow-spectrum agents) to each national total. Therefore, caution should be exercised when comparing countries with regard to levels of community and hospital antibacterial consumption, and the proportion of total antibacterial consumption comprised by community consumption. The national consumption data should be considered in the light of studies of the appropriateness of antibacterial prescribing, both in the community and in hospitals, within each nation.
Regardless of the degree of appropriateness of community antibacterial consumption in New Zealand, there is good evidence that high community antibacterial consumption has contributed to marked increases in antibacterial resistance in common bacterial pathogens. Very high levels of use of topical mupirocin and fusidic acid in New Zealand during the last two decades have correlated with the rapid emergence of high levels of resistance to these two agents in Staphylococcus aureus. 22, 23 Excessive community antibacterial consumption has also contributed to the rapid emergence of fluoroquinolone-resistant
Neisseria gonorrhoeae, and a rapid increase in the prevalence of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli. Whereas general practitioners were the prescribers of the overwhelming bulk of antibacterials dispensed in the community, other clinicians also contributed to the high level of community antibacterial consumption in New Zealand. A recent study reported 34% of patients undergoing a major surgical procedure in New Zealand public hospitals were dispensed an antibacterial within 30 days of discharge from hospital, with almost half of dispensing occurring within 2 days of discharge from hospital. 30 It seems very likely that these antibacterials were prescribed by members of the hospital team rather than the patients' general practitioner. The very high rate of these prescriptions is clearly excessive when compared with the low reported rate of wound infections (2.6%) in these patients. 30 Other specialist consultations, in emergency departments or outpatient clinics at public hospitals, or in private practices, plus prescribing by dentists and other healthcare workers, undoubtedly make a significant further contribution to community antibacterial dispensing. This warrants further investigation.
| WHAT IS NEW AND CONCLUSION
This study indicates that in those countries for which data are available, community dispensing comprises approximately 85%-95% of total antibacterial dispensing. In consequence, in most countries, efforts to slow the emergence of antibacterial resistance should devote significant resources to reducing community antibacterial consumption. Programmes to reduce antibacterial consumption within New
Zealand and elsewhere need to balance the benefits of slowing the spread of antibacterial resistance against the risks of under-treatment of serious infections in population groups with a high incidence of serious infectious diseases. 31 The success of such programmes will depend on improved understanding of antimicrobial stewardship among both the general population and those clinicians who prescribe antibacterials for use in the community.
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F I G U R E 1 Scatterplot of the proportion of total antibacterial consumption comprised by community consumption, in relation to total antibacterial consumption (DDDs/1000 population/d), for New Zealand and other nations for which recent published data were available [19] [20] [21] 
